Bristol-Myers stock gains on new Krazati label (NYSE:BMY)

FDA Headquarters - White Oak Campus

hapabapa

The U.S. Food and Drug Administration (FDA) on Friday greenlighted Bristol Myers Squibb’s (NYSE:BMY) marketing application to expand the label for its lung cancer therapy Krazati to include patients with colorectal cancer.

Accordingly, Krazati, added to Bristol Myers’ (BMY